<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787603</url>
  </required_header>
  <id_info>
    <org_study_id>PSInCor-Procalcitonin Clinical</org_study_id>
    <nct_id>NCT02787603</nct_id>
  </id_info>
  <brief_title>Procalcitonin in Early Antibiotic Interruption in Patient With Bacterial Pulmonary infeCtion and Acute Heart Failure</brief_title>
  <acronym>EPICAD</acronym>
  <official_title>Evaluation of Procalcitonin in the Early Antibiotic Therapy Interruption in Patient With Bacterial Pulmonary infeCtion and Decompensated Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Acute Heart Failure is frequently decompensated by pulmonary infection, but the
      diagnosis of pulmonary infection sometimes is difficult in these patients due to similar
      signals and clinical symptoms in both pathologies. Furthermore, when it is possible the
      diagnosis of pulmonary infection, physicians may have difficult to determine etiology and
      delaying antibiotic therapy. Procalcitonin (PCT) have been used like a biomarker to determine
      the period of use of antibiotics in patients with acute respiratory infections. It is
      specific for bacterial infections and it have showed as a marker of severity infection and
      may help to determine interruption period of antibiotic therapy in a safety way for the
      patient. Aim: Evaluate levels of PCT related to interruption of antibiotics in patients with
      decompensated acute heart failure (DAHF) with suspected bacterial pulmonary infection.
      Methods: In this pilot project will be included around 100 patients, randomized in two
      groups: group A (PCT levels may guide the interruption of antibiotic at day 5) or group B
      (antibiotic period will be determined by the physician without the knowledge of PCT levels).
      Will be collected laboratorial and clinical data at days 0,3 and 5. Both groups will be
      compared to evaluate PCT levels and total period of antibiotic therapy, hospitalization and
      readmission in 30 days. This study will determine the sensibility/specificity of PCT in
      patients with DAHF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a single-center study, randomized, controlled, prospective cohort and interventional
      not blind. DAHF diagnosis will consider symptoms, physical examination, x ray and other image
      methods and BNP ou NTproBNP levels. Pulmonary infection diagnosis will &quot;Infectious Disease
      Society of America / American Thoracic Society Consensus Guidelines on the Management of
      Community-Acquired Pneumonia in Adults&quot; criteria, that include fever, cough, sputum,
      pleuritic pain, positive pulmonary image and physical examination. PCT and NTproBNP levels
      will be measured in miniVIDAS® (bioMérieux Clinical Diagnostics, France). Statistics includes
      descriptive analysis. Parametric data will be evaluated using T test and non parametric data
      with Mann-Whitney-Wilcoxon test. Multivariative analysis related to diagnosis, mortality and
      morbidity will be performed by Cox regression model. Sensibility and specificity will be
      calculated by ROC curve. Statistical significancy will be considered when p&lt;0.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total period of antibiotic therapy</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospitalization</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCT levels during antibiotic therapy</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <condition>Pneumonia, Bacterial</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interruption of antibiotic treatment due to PCT measurement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Antibiotic therapy period will be determined by the physician without the knowledge of PCT levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interruption of antibiotic treatment due to PCT measurement</intervention_name>
    <description>In group A at day 5, if the patient shows no clinical signs of infection and PCT levels &lt; 0,25ng/mL OR PCT &gt; 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.</description>
    <arm_group_label>group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DAHF diagnosis and suspected pulmonary infection

          -  BNP ≥ 500 pg/mL or NTproBNP ≥ 450 pg/mL for patients until 50 years old.

          -  BNP ≥ 500 pg/mL or NTproBNP ≥ 900 pg/mL for patients with 51 - 75 years old.

          -  BNP ≥ 500 pg/mL or NTproBNP ≥ 1800 pg/mL for patients older than 75 years.

        Exclusion Criteria:

          -  Antibiotic use (oral or endovenous) in the last 15 days;

          -  Acute coronary syndrome;

          -  Creatinine &gt; 3,0 mg/dL or hemodialysis;

          -  Pregnancy;

          -  Second suspectec infection;

          -  Suspected pulmonary thromboembolism;

          -  cancer;

          -  myocarditis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mucio Tavares, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidade Clínica de Emergência</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidade Clínica de Emergência - Instituto do Coração InCor HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Maisel A, Neath SX, Landsberg J, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Möckel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Christenson RH, Potocki M, McCord J, Terracciano G, Hartmann O, Bergmann A, Morgenthaler NG, Anker SD. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail. 2012 Mar;14(3):278-86. doi: 10.1093/eurjhf/hfr177. Epub 2012 Feb 2.</citation>
    <PMID>22302662</PMID>
  </results_reference>
  <results_reference>
    <citation>Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011 Sep 22;9:107. doi: 10.1186/1741-7015-9-107. Review.</citation>
    <PMID>21936959</PMID>
  </results_reference>
  <results_reference>
    <citation>Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, Nicholson KG, Brightling CE. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011 Jun;139(6):1410-1418. doi: 10.1378/chest.10-1747. Epub 2010 Oct 28.</citation>
    <PMID>21030489</PMID>
  </results_reference>
  <results_reference>
    <citation>Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M; PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010 Feb 6;375(9713):463-74. doi: 10.1016/S0140-6736(09)61879-1. Epub 2010 Jan 25.</citation>
    <PMID>20097417</PMID>
  </results_reference>
  <results_reference>
    <citation>Schuetz P, Kutz A, Grolimund E, Haubitz S, Demann D, Vögeli A, Hitz F, Christ-Crain M, Thomann R, Falconnier C, Hoess C, Henzen C, Marlowe RJ, Zimmerli W, Mueller B; ProHOSP Study Group. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol. 2014 Aug 20;175(3):464-72. doi: 10.1016/j.ijcard.2014.06.022. Epub 2014 Jun 27.</citation>
    <PMID>25005339</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

